Navigation Links
Takeda and Zinfandel Pharmaceuticals Sign Licensing Agreement for Alzheimer's Disease Biomarker in Combination with Pioglitazone
Date:1/10/2011

OSAKA, Japan and DURHAM, N.C., Jan. 10, 2011 /PRNewswire/ -- Takeda Pharmaceutical Company Limited and Zinfandel Pharmaceuticals, Inc. today announced that they have entered into an exclusive, worldwide licensing agreement regarding Zinfandel's TOMM40 assay as a biomarker for the risk of Alzheimer's disease in high-risk older adults with normal cognition. The companies will study pioglitazone in connection with the TOMM40 biomarker and Alzheimer's disease. Pioglitazone is the active ingredient currently marketed in Takeda's ACTOS® (pioglitazone HCl).

The TOMM40 biomarker, recently discovered by a team led by Allen Roses, M.D., Chief Executive Officer of Zinfandel, is being developed to identify individuals at high risk of developing Alzheimer's disease within the subsequent five years. Under this license agreement, Takeda and Zinfandel will attempt to prospectively validate the TOMM40 biomarker as a test of individual risk.

"There is intense interest within the medical community in identifying treatments to help delay progression or potentially prevent the onset of Alzheimer's disease, in an effort to reduce the burden of this disease," said Shigenori Ohkawa, Ph.D., Chief Scientific Officer, Takeda Pharmaceutical Company Limited. "We are energized by this partnership and the opportunity to develop an effective treatment for healthy at-risk older adults."

Under the terms of agreement, Zinfandel will receive an upfront payment of $9 million and subsequent payments of up to $78 million for development milestones from Takeda. Additional commercial milestones and royalties were also outlined in the agreement. Takeda will obtain an exclusive license, with the right to sublicense, develop, make, use and commercialize the TOMM40 biomarker assay, and to use the assay to identify high-risk older adults who would be candidates for clinical trials with pioglitazone to evaluate its utility.

"At Zinfandel, we have been exploring pharmacogene
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited; Zinfandel Pharmaceutcals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Takeda San Francisco, Inc. Appoints Gregory Landes, Ph.D. Vice President of Antibody Research
2. FDA Continues Review of Takedas New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
4. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
5. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
6. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
7. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
8. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
9. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
10. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
11. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... July 23, 2014 DuPont Pioneer announced ... as vice president of Agricultural Biotechnology (ABT), effective July ... he served most recently as president, chief executive officer ... business leadership in the seed and crop protection industry ... Paul E. Schickler , president of DuPont Pioneer. “I ...
(Date:7/23/2014)... , July 23, 2014  Sofinnova Ventures, a ... announced the closing of Sofinnova Venture Partners IX, L.P. ... excess of the initial fund target of $425 million. ... successful biotechnology companies. Consistent with recent funds, SVP IX ... stage clinical programs, along with select investments in earlier ...
(Date:7/23/2014)... Adult stem cells that are required ... not magical. However, many current regenerative medicine ... if they were magical. , Many current clinical ... “stem cell tourism,” are evaluating heterologous tissue stem ... regenerative medicine therapies. In reality, these are not ...
(Date:7/22/2014)... of Standards and Technology (NIST) and California Institute ... for an atomic clock that is based on ... The microcomb clock, featured on the cover of ... Optica ,* is the first demonstration of all-optical ... of optical frequencies to lower microwave frequencies. (Optical ...
Breaking Biology Technology:DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3Sofinnova Raises $500 Million Biotech Venture Fund 2The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 2The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 4The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 5'Comb on a chip' powers new NIST/Caltech atomic clock design 2
... work showing how nanowires carved in impurity-laden diamond ... developed a scalable manufacturing process to craft arrays ... photon control. The development supports efforts to ... stage for diamond-based microchips. Additionally, the technology ...
... 2011 Applied Precision is proud to announce ... super-resolution microscopy system at McGill University in Montreal, ... is a super-resolution microscope utilizing proven three-dimensional structured ... in volume resolution and outstanding widefield imaging capabilities. ...
... Ohio, Oct. 18, 2011 Minimally Invasive Devices, Inc ... new product, FloShield PLUS , utilizing the novel Flo-X ... of the end of the laparoscope without removal from the ... MID,s FloShield laparoscopic visualization system. In the first 19 FloShield ...
Cached Biology Technology:Diamonds, silver and the quest for single photons 2Diamonds, silver and the quest for single photons 3Applied Precision Announces the 25th Installation of Its DeltaVision OMX Super-Resolution Microscope at McGill University 2
(Date:7/23/2014)... Tracking of blue whales by satellite over a 15-year ... whales consistently return to feed in specific locations each ... in the open-access journal PLOS ONE by ... data may be used to mitigate human threats to ... has been slow to recover since the establishment of ...
(Date:7/23/2014)... cystic fibrosis patients, scientists at the UNC School of ... that a new CF drug counteracts the intended beneficial ... published today in the journal Science Translational Medicine ... and loses its ability to function properly when in ... several insights into how novel CF pharmacotherapies could be ...
(Date:7/23/2014)... , , , , , ... , , , , ... diseases and extend healthy lifespan. The idea, they argue, would be to target the... , , ... , , , , , ... , , , , , , , Medicine ...
Breaking Biology News(10 mins):Blue whales' dangerous feeding grounds 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 3UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 4Strategy proposed for preventing diseases of aging 2Strategy proposed for preventing diseases of aging 3Strategy proposed for preventing diseases of aging 4Strategy proposed for preventing diseases of aging 5
... several proteins in mice that might act as biomarkers ... step to finding a more reliable way to detect ... teenagers use illegally to boost muscle and reduce fat. ... San Francisco today, scientists John Kopchick and Juan Ding ...
... the White House must be enhanced so that the ... nationfrom energy and the environment, to national security, and ... collaborate internationally. The report,s primary recommendations are that: ... respected leader to be Assistant for Science and Technology ...
... 2008 Mary Tyler Moore, the Juvenile Diabetes Research ... M.D., presented the sixth annual "Excellence in Clinical Research ... annual conference today in Washington, DC. The recipients ... director of the JDRF Gene Therapy Center for Diabetes ...
Cached Biology News:Scientists find potential protein biomarkers for growth hormone 2White House science office needs upgrade 2White House science office needs upgrade 3Florida researchers receive JDRF 'Excellence in Clinical Research Award' 2